• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

UPDATE: Insulet hits the road in Europe after landing EU approval for its OmniPod insulin system

April 28, 2009 By drugdelivery

MassDevice caught Rob Campbell, Insulet Corp.‘s vice president of clinical research, on his way to dinner in Paris after a day spent lining up a distribution deal for the company’s flagship OmniPod insulin management system.

European Union regulators gave the nod for the device to hit the market there, meaning the Bedford-based diabetes device maker is cleared to start selling the OmniPod in countries that recognize the EU’s CE Mark.

“We were very pleased about the CE Mark, obviously,” Campbell told us, adding that he and vice president of international operations (and former CFO) Carsten Boess are making the rounds in Europe to arrange a distribution agreement. “We’ve been all over in the last two days — Germany, France, Scandinavia.”

The next stop for the young company, founded in 2000, is likely Asia, Campbell added.

“We’ve outgrown our manufacturing constraints in the U.S., which led us to look to outside markets,” he said. “There’s a long list outside of the EU, but the CE Mark certainly helps us with the establishment of markets in France and Germany.”

The OmniPod will be available in “selected markets” in Europe this year and more widely in 2010, according to a press release earlier today.

The device is a continuous insulin delivery system that uses a wireless, self-adhesive delivery device worn under clothing that connects to a hand-held programming device. It monitors blood sugar levels and delivers insulin to help regulate diabetic patients’ glucose levels.

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS